GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
142.59
-2.72 (-1.87%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close145.31
Open146.06
Bid140.00 x 800
Ask144.89 x 800
Day's Range141.77 - 148.38
52 Week Range101.07 - 179.65
Volume404,105
Avg. Volume515,050
Market Cap4.612B
Beta (3Y Monthly)2.89
PE Ratio (TTM)N/A
EPS (TTM)-8.74
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est178.33
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Investor Expectations to Drive Momentum within Motorola Solutions, Shire plc, Bitauto, GRIDSUM HOLDING, GW Pharmaceuticals, and Actinium Pharmaceuticals — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE2 days ago

    Stocks in Position to Beat the Failing Market

    HENDERSON, NV / ACCESSWIRE / October 18, 2018 / There has been some bad news in the market recently causing some securities to sell off. This has made for some desirable buying opportunities for savvy ...

  • Marijuana Stocks to Watch in October -- and Into 2019
    Motley Fool4 days ago

    Marijuana Stocks to Watch in October -- and Into 2019

    Looking for a marijuana stocks list with key data included? Look no further.

  • ACCESSWIRE5 days ago

    Why This Company is Set for a Major Breakout

    HENDERSON, NV / ACCESSWIRE / October 15, 2018 / With the broader market tanking it is likely investors will find safe haven in cannabis and biotech stocks because they are both innovative sectors. An incredibly ...

  • 5 of the Most Unique Marijuana Stocks
    Motley Fool5 days ago

    5 of the Most Unique Marijuana Stocks

    These pot stocks stand out in a very crowded field.

  • ACCESSWIRE5 days ago

    Today's Research Reports on Trending Tickers: GW Pharmaceuticals and Aerie Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / U.S. markets bounced on Friday, erasing some of the losses for the week, as the third quarter earnings season kicked off. The Dow Jones Industrial Average ...

  • How to Invest in Marijuana Stocks
    Motley Fool8 days ago

    How to Invest in Marijuana Stocks

    Seven straightforward steps to help you invest in high-growth -- but high-risk -- marijuana stocks.

  • ACCESSWIRE10 days ago

    Top Beverage Companies Entering CBD

    HENDERSON, NV / ACCESSWIRE / October 10, 2018 / Molson Coors became the latest major beverage company to announce plans to start their own CBD beverage arm. Coca-Cola and InBev have also announced similar ...

  • Marijuana ETFs: How to Find the Best Exchange-Traded Funds
    Motley Fool11 days ago

    Marijuana ETFs: How to Find the Best Exchange-Traded Funds

    If you're interested in profiting from the marijuana movement, you might want to consider owning a marijuana exchange-traded fund.

  • Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
    Motley Fool13 days ago

    Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

    Despite getting lumped in with riskier marijuana stocks, these two biotechs are worth a closer look.

  • Why GW Pharmaceuticals Stock Jumped 17.7% in September
    Motley Fool14 days ago

    Why GW Pharmaceuticals Stock Jumped 17.7% in September

    This marijuana stock had a good month last month thanks to a regulatory first. Here's what investors should know.

  • GW Pharmaceuticals: Recommendations and Market Capitalization
    Market Realist15 days ago

    GW Pharmaceuticals: Recommendations and Market Capitalization

    GW Pharmaceuticals (GWPH) has developed prescription medicines derived from the cannabis plant for the treatment of spasticity from multiple sclerosis. Its portfolio includes clinical stage cannabinoid products focused on the treatment of neurological conditions.

  • GW Pharmaceuticals: Q3 Performance, Q4 Estimates
    Market Realist15 days ago

    GW Pharmaceuticals: Q3 Performance, Q4 Estimates

    GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.

  • Marijuana-Focused Biotech Companies in Q3: Are They Performing?
    Market Realist15 days ago

    Marijuana-Focused Biotech Companies in Q3: Are They Performing?

    Biotechnology companies focused on marijuana-based products include GW Pharmaceuticals (GWPH), Cara Therapeutics (CARA), and Insys Therapeutics (INSY). In this series, we’ll look at these stocks and how they performed in the third quarter.

  • ACCESSWIRE15 days ago

    Cannabis Industry Service Provider Solving Major Challenges

    HENDERSON, NV / ACCESSWIRE / October 5, 2018 / One of the major reasons cannabis stocks are doing so well is because they are potential solutions to long standing challenges, such as the opioid epidemic. ...

  • GlobeNewswire15 days ago

    GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs, Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs

    GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of 1,900,000 American Depositary Shares (“ADSs”) and the full exercise by the underwriters of their option to purchase 285,000 additional ADSs from GW at a price to the public of $158.00 per ADS, raising gross proceeds of $345,230,000 (before deducting underwriting discounts, commissions and offering expenses).

  • GlobeNewswire18 days ago

    GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million

    GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company.

  • Investor's Business Daily18 days ago

    Dow Jones Futures: Hot IPO Stitch Fix Dives, Marijuana Stocks India Global, New Age Beverages Swing Wildly

    Stock futures: Hot IPO Stitch Fix earnings topped, but other metrics missed. Stitch Fix stock dived. Marijuana plays New Age Beverages, India Globalization and DavidsTea were volatile.

  • ACCESSWIRE18 days ago

    DEA Rescheduling Makes CBD Stocks Blazing Hot

    HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The DEA has just made a move that makes that has investors fired up.Last week, U.S. Drug Enforcement Administration has taken some cannabidiol off the most restrictive class of controlled substances, a move that allows the sale of the first nonsynthetic, cannabis-derived medicine to win federal approval. The agency announced Thursday that drugs including "finished dosage formulations" of CBD with THC below 0.1% will be considered Schedule 5 drugs, as long as the medications have been approved by the U.S. Food and Drug Administration. This has made CBD stocks even hotter than they have been.CBD stallwarts like GW Pharma, who was a large reason for this ruling are obviously benefitting, however, for investors looking to maximize their profit potential from this ruling it's beneficial to dig a little deeper.

  • GlobeNewswire19 days ago

    GW Pharmaceuticals Announces Proposed Public Offering of ADSs

    GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform and whose U.S. subsidiary is Greenwich Biosciences, announced today that it intends to sell, subject to market and other conditions, $300 million of American Depositary Shares (“ADSs”) representing ordinary shares of GW on the Nasdaq Global Market in an underwritten U.S. public offering.  GW expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of ADSs at the offering price. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • ACCESSWIRE19 days ago

    The Hottest CBD Stocks

    HENDERSON, NV / ACCESSWIRE / October 1, 2018 / With the DEA rescheduling CBD the top is off, and the time is now to find CBD companies before missing the boat.CBD is a very lucrative business, because ...

  • The Best-Performing Marijuana Stock of All Time (Hint: It's Probably Not Who You Think It Is)
    Motley Fool20 days ago

    The Best-Performing Marijuana Stock of All Time (Hint: It's Probably Not Who You Think It Is)

    The biggest market cap or the most hype doesn't always translate to the greatest stock performance.

  • Even if Sessions Is Fired, Marijuana Legalization Is a Long Shot
    Motley Fool21 days ago

    Even if Sessions Is Fired, Marijuana Legalization Is a Long Shot

    Losing the most vocal critic of legal cannabis wouldn't change much in the U.S.

  • Pot Stocks & ETF: Risks and Rewards
    Zacks22 days ago

    Pot Stocks & ETF: Risks and Rewards

    Here is what investors need to know about risks and rewards of investing in the emerging marijuana industry.

  • ACCESSWIRE22 days ago

    3 Marijuana Stocks That Could Close Your Week With A Bang

    CORAL GABLES, FL / ACCESSWIRE / September 28, 2018 / It's no secret that marijuana stocks are capturing a lot of attention lately and because of this, it's no wonder why one of the few cannabis ETFs that track the industry, the ETFMG Alternative Harvest ETF (MJ), has jumped by more than 30% since March. Alcoholic-beverage maker Constellation Brands' $4 billion investment in Canadian marijuana company Canopy Growth was a big catalyst in recent weeks. This was followed up by a number of other companies like Molson Coors and even Coca-Cola eyeing the cannabis market.